ESOPHAGEAL ADENOCARCINOMA
Clinical trials for ESOPHAGEAL ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new ESOPHAGEAL ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for ESOPHAGEAL ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Experimental cancer pill targets Hard-to-Treat tumors
Disease control TerminatedThis early-stage study tested an experimental oral drug called PRT7732 in people with advanced solid tumors that have a specific genetic mutation (SMARCA4). The main goals were to check safety, find the right dose, and see if the drug could shrink tumors. The study was terminated…
Matched conditions: ESOPHAGEAL ADENOCARCINOMA
Phase: PHASE1 • Sponsor: Prelude Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
Experimental cancer drug TAK-500 tested in 61 patients – study halted early
Disease control TerminatedThis early-phase trial tested an experimental drug called TAK-500, alone or with the immunotherapy pembrolizumab, in 61 adults with advanced solid tumors like pancreatic, liver, and lung cancer. The main goals were to check safety and see if the drug could shrink tumors. The stud…
Matched conditions: ESOPHAGEAL ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Takeda • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
New cancer drug BLU-222 tested in early trial – but study stopped early
Disease control TerminatedThis early-phase trial tested a new drug called BLU-222, alone or with other medicines, in about 50 people with advanced solid tumors (including certain breast, ovarian, and stomach cancers). The goal was to find a safe dose and see if it shrinks tumors. However, the study was te…
Matched conditions: ESOPHAGEAL ADENOCARCINOMA
Phase: PHASE1 • Sponsor: Blueprint Medicines Corporation • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
Experimental cancer drug ASP2074 trial halted early
Disease control TerminatedThis early-phase trial tested a new drug called ASP2074 in 23 adults with advanced solid tumors that had spread or couldn't be removed by surgery. The goal was to find a safe dose and check for side effects. The study was terminated early, so results are limited.
Matched conditions: ESOPHAGEAL ADENOCARCINOMA
Phase: PHASE1 • Sponsor: Astellas Pharma Global Development, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
Cancer combo trial halted early: what we know
Disease control TerminatedThis phase 2 trial tested two drugs—ulixertinib and hydroxychloroquine—in 47 people with advanced gastrointestinal cancers that have certain genetic mutations (MAPK pathway). The goal was to see if the combination could shrink tumors. However, the study was terminated early, so t…
Matched conditions: ESOPHAGEAL ADENOCARCINOMA
Phase: PHASE2 • Sponsor: BioMed Valley Discoveries, Inc • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC